Publikation

Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.

Wissenschaftlicher Artikel/Review - 07.12.2021

Bereiche
PubMed
DOI
Kontakt

Zitation
Purde M, Niederer R, Wagner N, Diem S, Berner F, Hasan Ali O, Hillmann D, Bergamin I, Jörger M, Risch M, Niederhauser C, Lenz T, Früh M, Risch L, Semela D, Flatz L. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. J Cancer Res Clin Oncol 2021; 148:647-656.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
J Cancer Res Clin Oncol 2021; 148
Veröffentlichungsdatum
07.12.2021
eISSN (Online)
1432-1335
Seiten
647-656
Kurzbeschreibung/Zielsetzung

Immune checkpoint inhibitor (ICI)-induced hepatitis belongs to the frequently occurring immune-related adverse events (irAEs), particularly with the combination therapy involving ipilimumab and nivolumab. However, predisposing factors predicting the occurrence of ICI-induced hepatitis are barely known. We investigated the association of preexisting autoantibodies in the development of ICI-induced hepatitis in a prospective cohort of cancer patients.